Namely, unlike high-volume anti-HAV serology, HAV RNA testing is rarely requested by clinicians, and this is usually after detecting anti-HAV IgM in patients with a strongly suspected false-positive anti-HAV IgM result, in individuals with negative and/or indeterminate anti-HAV IgM results when an early phase of acute hepatitis A is considered, or in severely immunocompromised patients (4, 10). The gene discussed is CD40LG; the disease is hepatitis A virus infection.